[Congressional Record Volume 167, Number 90 (Monday, May 24, 2021)]
[Senate]
[Page S3340]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 1922. Ms. WARREN (for herself and Mr. Rubio) submitted an 
amendment intended to be proposed to amendment SA 1502 proposed by Mr. 
Schumer to the bill S. 1260, to establish a new Directorate for 
Technology and Innovation in the National Science Foundation, to 
establish a regional technology hub program, to require a strategy and 
report on economic security, science, research, innovation, 
manufacturing, and job creation, to establish a critical supply chain 
resiliency program, and for other purposes; which was ordered to lie on 
the table; as follows:

        At the end of title III of division E, add the following:

     SEC. 5311. REPORT ON FOREIGN INVESTMENT IN PHARMACEUTICAL 
                   INDUSTRY.

       (a) In General.--Not later than one year after the date of 
     the enactment of this Act, and annually thereafter, the 
     Federal Trade Commission, in consultation with the Secretary 
     of Commerce, shall submit to the appropriate congressional 
     committees, the Secretary of Health and Human Services, the 
     Committee on Foreign Investment in the United States, and the 
     Commissioner of Food and Drugs, a report on foreign 
     investment in the pharmaceutical industry of the United 
     States.
       (b) Elements.--The report required by subsection (a) shall 
     include an assessment of--
       (1) the supply chain of the pharmaceutical industry of the 
     United States and the effect of concentration and reliance on 
     foreign manufacturing within that industry;
       (2) the effect of foreign investment in the pharmaceutical 
     industry of the United States on domestic capacity to produce 
     drugs and active and inactive ingredients of drugs; and
       (3) the effect of foreign investment in technologies or 
     other products for sequencing or storage of DNA, including 
     genome and exome analysis, in the United States, including 
     the effect of such investment on the capacity to sequence or 
     store DNA in the United States.
       (c) Authority.--The Federal Trade Commission shall have 
     authority under section 6 of the Federal Trade Commission Act 
     (15 U.S.C. 46) to conduct the studies required to prepare the 
     report required by subsection (a).
       (d) Publication.--The Federal Trade Commission shall 
     publish an unclassified summary of the report required by 
     subsection (a) on a publicly available internet website of 
     the Commission.
       (e) Appropriate Congressional Committees Defined.--In this 
     section, the term ``appropriate congressional committees'' 
     means--
       (1) the Committee on Banking, Housing, and Urban Affairs, 
     the Committee on Health, Education, Labor, and Pensions, the 
     Committee on Armed Services, the Committee on Foreign 
     Relations, the Committee on Commerce, Science, and 
     Transportation, and the Committee on Appropriations of the 
     Senate; and
       (2) the Committee on Financial Services, the Committee on 
     Energy and Commerce, the Committee on Armed Services, the 
     Committee on Foreign Affairs, and the Committee on 
     Appropriations of the House of Representatives.
                                 ______